Oral oncology最新文献

英文中文

Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-26 DOI: 10.1016/j.oraloncology.2025.107218

Wen-Jie Wu , Pu-Gen An , Qian Liu , Zi-Qi Zhang , Xiao Hu , Jie Yao , Jie Zhang

Background

The outcomes and quality of life of patients with locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC) following upfront surgery (US) are suboptimal. The optimal neoadjuvant therapy involving programmed death-1 inhibitors still remains unknown. We aimed to investigate the antitumor efficacy and quality-of-life benefits of neoadjuvant chemoimmunotherapy (NACI) and compare them with those of US for LAOOPSCC.

Methods

A total of 570 patients with OOPSCC who underwent surgical treatment between January 2021 and January 2023 were initially reviewed and we obtained 51 unbiased patients in each of the NACI and US groups through propensity score matching based on age, sex, clinical T and N stage. The antitumor efficacy in patients in the NACI group was evaluated with the pathological response. The postoperative quality of life, as assessed with the EORTC Quality of Life Questionnaire Head and Neck 35, as well as disease-free survival and overall survival, were compared between the groups.

Results

In the NACI group, the major pathological response rate was 58.8 % (30/51), and the objective response rate was 66.7 % (34/51). In NACI group, In the NACI group, patients experienced a shorter operative time (p = 0.001) and a reduced length of hospitalization post-surgery (p = 0.041), along with less intraoperative blood loss (p < 0.001) and fewer free flap reconstructions (p < 0.001). Compared with the patients in the US group, those in the NACI group had significantly better postoperative quality of life, including the sensory function (12.7 vs. 23.0, p = 0.021), speech problems (17.3 vs. 35.1, p < 0.001), social eating (20.8 vs. 31.0, p = 0.020), social contact (19.8 vs. 36.5, p < 0.001) and feeling ill (41.2 vs. 51.6, p = 0.021). There was no significant statistical difference in OS (p = 0.825) and DFS (p = 0.473) between the two groups.

Conclusion

The findings demonstrate the safety and feasibility of NACI and the de-escalation surgery after NACI is worth promoting to improve patient postoperative quality of life.

{"title":"Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis","authors":"Wen-Jie Wu , Pu-Gen An , Qian Liu , Zi-Qi Zhang , Xiao Hu , Jie Yao , Jie Zhang","doi":"10.1016/j.oraloncology.2025.107218","DOIUrl":"10.1016/j.oraloncology.2025.107218","url":null,"abstract":"<div><h3>Background</h3><div>The outcomes and quality of life of patients with locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC) following upfront surgery (US) are suboptimal. The optimal neoadjuvant therapy involving programmed death-1 inhibitors still remains unknown. We aimed to investigate the antitumor efficacy and quality-of-life benefits of neoadjuvant chemoimmunotherapy (NACI) and compare them with those of US for LAOOPSCC.</div></div><div><h3>Methods</h3><div>A total of 570 patients with OOPSCC who underwent surgical treatment between January 2021 and January 2023 were initially reviewed and we obtained 51 unbiased patients in each of the NACI and US groups through propensity score matching based on age, sex, clinical T and N stage. The antitumor efficacy in patients in the NACI group was evaluated with the pathological response. The postoperative quality of life, as assessed with the EORTC Quality of Life Questionnaire Head and Neck 35, as well as disease-free survival and overall survival, were compared between the groups.</div></div><div><h3>Results</h3><div>In the NACI group, the major pathological response rate was 58.8 % (30/51), and the objective response rate was 66.7 % (34/51). In NACI group, In the NACI group, patients experienced a shorter operative time (p = 0.001) and a reduced length of hospitalization post-surgery (p = 0.041), along with less intraoperative blood loss (p < 0.001) and fewer free flap reconstructions (p < 0.001). Compared with the patients in the US group, those in the NACI group had significantly better postoperative quality of life, including the sensory function (12.7 vs. 23.0, p = 0.021), speech problems (17.3 vs. 35.1, p < 0.001), social eating (20.8 vs. 31.0, p = 0.020), social contact (19.8 vs. 36.5, p < 0.001) and feeling ill (41.2 vs. 51.6, p = 0.021). There was no significant statistical difference in OS (p = 0.825) and DFS (p = 0.473) between the two groups.</div></div><div><h3>Conclusion</h3><div>The findings demonstrate the safety and feasibility of NACI and the de-escalation surgery after NACI is worth promoting to improve patient postoperative quality of life.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107218"},"PeriodicalIF":4.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-26 DOI: 10.1016/j.oraloncology.2025.107227

M. Wiczuk-Wiczewska , J. Bernaciak , P. Nogal , A. Bugaj , J. Jackowska

Laryngeal squamous cell carcinoma (SCC) is a common malignancy of the head and neck, typically presenting in older patients with a history of smoking or alcohol use. However, its progression can be unpredictable, with cases of long-term dormancy followed by rapid progression. We report a case of a 71-year-old male with an 18-year history of otolaryngological treatment who presented with a newly diagnosed laryngeal SCC after multiple benign findings in previous laryngoscopies. The patient underwent CO₂ laser excision of the tumour, and subsequent histopathological examination confirmed the presence of SCC. Follow-up imaging and microlaryngoscopy revealed no residual tumour or metastasis. The patient remains under surveillance.

引用次数: 0

Commentary on, “Oncologic significance of the lateral margin in buccal cancer.”

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-26 DOI: 10.1016/j.oraloncology.2025.107232

Gnanaprakash Jeyaraj

引用次数: 0

Comments on “Achieving negative superficial resection margins with NBI and white light in carcinoma oral cavity: Could it be a norm?”

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-26 DOI: 10.1016/j.oraloncology.2025.107226

F. Boscolo Nata, G. Tirelli

引用次数: 0

Application of patient derived xenograft model in personalized drug screening for chondrosarcoma of head and neck: A preclinical study

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-24 DOI: 10.1016/j.oraloncology.2025.107222

Yufei Hua , Zhiyong Guo , Ying Wang , Chunjie Li , Bing Yan

Objectives

The effect of radiotherapy and chemotherapy on head and neck chondrosarcoma (HNCS) has not been unanimously determined because of the rarity of HNCS. Patient-Derived Xenograft (PDX) model is considered to be a good preclinical model for new drug development and personalized drug screening. We performed this study to investigate the preclinical application and value of PDX model in drug screening for HNCS.

Materials and methods

Tumor tissues of a patient with HNCS who underwent surgical treatment in the Department of Head and Neck Oncology of our hospital were collected. The PDX model was established in NCG mice and successfully passed to the P3 generation in nude mice. After the tumor grew to a certain size, three drugs targeting different molecules (Nilotinib, Regorafenib, Rapamycin) were given respectively. The treatment efficiency and safety were observed.

Results

NCG mouse is a kind of mouse that can successfully establish the PDX model of HNCS, and the PDX model can be stably passed in nude mice. The PDX tumor show similar histopathological characteristics to the parent tumors. After stable passaging, the mesenchymal cells were reduced and the tumor cells were increased in PDX tumor, making it easier to extract primary tumor cells. In the P3 PDX tumor, oral administration of nilotinib and regorafenib or intraperitoneal injection of rapamycin could significantly reduce the tumor size.

Conclusion

For rare tumors such as HNCS, PDX model is a good preclinical model for personalized drug screening and has good clinical application value.

{"title":"Application of patient derived xenograft model in personalized drug screening for chondrosarcoma of head and neck: A preclinical study","authors":"Yufei Hua , Zhiyong Guo , Ying Wang , Chunjie Li , Bing Yan","doi":"10.1016/j.oraloncology.2025.107222","DOIUrl":"10.1016/j.oraloncology.2025.107222","url":null,"abstract":"<div><h3>Objectives</h3><div>The effect of radiotherapy and chemotherapy on head and neck chondrosarcoma (HNCS) has not been unanimously determined because of the rarity of HNCS. Patient-Derived Xenograft (PDX) model is considered to be a good preclinical model for new drug development and personalized drug screening. We performed this study to investigate the preclinical application and value of PDX model in drug screening for HNCS.</div></div><div><h3>Materials and methods</h3><div>Tumor tissues of a patient with HNCS who underwent surgical treatment in the Department of Head and Neck Oncology of our hospital were collected. The PDX model was established in NCG mice and successfully passed to the P3 generation in nude mice. After the tumor grew to a certain size, three drugs targeting different molecules (Nilotinib, Regorafenib, Rapamycin) were given respectively. The treatment efficiency and safety were observed.</div></div><div><h3>Results</h3><div>NCG mouse is a kind of mouse that can successfully establish the PDX model of HNCS, and the PDX model can be stably passed in nude mice. The PDX tumor show similar histopathological characteristics to the parent tumors. After stable passaging, the mesenchymal cells were reduced and the tumor cells were increased in PDX tumor, making it easier to extract primary tumor cells. In the P3 PDX tumor, oral administration of nilotinib and regorafenib or intraperitoneal injection of rapamycin could significantly reduce the tumor size.</div></div><div><h3>Conclusion</h3><div>For rare tumors such as HNCS, PDX model is a good preclinical model for personalized drug screening and has good clinical application value.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107222"},"PeriodicalIF":4.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-22 DOI: 10.1016/j.oraloncology.2025.107187

Fan Yang , Wenjing Peng , Haoran Wei , Xiaolu Li , Xiaoduo Yu , Lin Li , Yanfeng Zhao , Lizhi Xie , Meng Lin , Hongmei Zhang

Purpose

To evaluate the value of model-free parameters (virtual magnetic resonance elastography [vMRE] and signature index [S-index]) and tumor aggressiveness indicators (contralateral pharyngeal recess invasion [CPRI] and tumor growth type [TGT]) in forecasting 5-year treatment outcomes in nasopharyngeal carcinoma (NPC).

Materials and Methods

A total of 106 patients were included in this study. Only two b-values were employed to calculate vMRE and S-index. Univariate and multivariate Cox analyses were conducted with clinical factors as confounding variables. Multivariate logistic analysis was used to construct multiple models. The additional value of CPRI and TGT was evaluated through net reclassification improvement index (NRI) and integrated discrimination improvement (IDI). Model performance and robustness were evaluated.

Results

The predictive performance of vMRE and S-index (area under the curve [AUC]: 0.620 ∼ 0.639) was comparable to that of model-based parameters (AUC: 0.570 ∼ 0.658, all P ≥ 0.366). CPRI and TGT independently predicted progression-free survival (PFS) and overall survival (OS). Combined models significantly outperformed than the TNM stage model (all P ≤ 0.002) and vMRE-based or S-index-based model (all NRI ≥ 0.105 and IDI ≥ 0.085) in terms of 5-year OS (AUC: 0.840 ∼ 0.843) and 5-year PFS (AUC: 0.786 ∼ 0.793). The combined model demonstrated robust performance through Hosmer-Lemeshow test, cross-validation (iteration = 1000), 7:3 validation (chronologically or randomly), and post-hoc subgroup analysis.

Conclusion

The advent of vMRE and S-index has streamlined the clinical applications without compromising the value of IVIM technique. Incorporating CPRI and TGT has further enhanced the predictive performance.

Clinical relevance statement

Only two b-values are needed to calculate vMRE and S-index, which, along with CPRI and TGT, are pivotal in forecasting long-term survival in patients with NPC.

{"title":"Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC","authors":"Fan Yang , Wenjing Peng , Haoran Wei , Xiaolu Li , Xiaoduo Yu , Lin Li , Yanfeng Zhao , Lizhi Xie , Meng Lin , Hongmei Zhang","doi":"10.1016/j.oraloncology.2025.107187","DOIUrl":"10.1016/j.oraloncology.2025.107187","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the value of model-free parameters (virtual magnetic resonance elastography [vMRE] and signature index [S-index]) and tumor aggressiveness indicators (contralateral pharyngeal recess invasion [CPRI] and tumor growth type [TGT]) in forecasting 5-year treatment outcomes in nasopharyngeal carcinoma (NPC).</div></div><div><h3>Materials and Methods</h3><div>A total of 106 patients were included in this study. Only two b-values were employed to calculate vMRE and S-index. Univariate and multivariate Cox analyses were conducted with clinical factors as confounding variables. Multivariate logistic analysis was used to construct multiple models. The additional value of CPRI and TGT was evaluated through net reclassification improvement index (NRI) and integrated discrimination improvement (IDI). Model performance and robustness were evaluated.</div></div><div><h3>Results</h3><div>The predictive performance of vMRE and S-index (area under the curve [AUC]: 0.620 ∼ 0.639) was comparable to that of model-based parameters (AUC: 0.570 ∼ 0.658, all P ≥ 0.366). CPRI and TGT independently predicted progression-free survival (PFS) and overall survival (OS). Combined models significantly outperformed than the TNM stage model (all P ≤ 0.002) and vMRE-based or S-index-based model (all NRI ≥ 0.105 and IDI ≥ 0.085) in terms of 5-year OS (AUC: 0.840 ∼ 0.843) and 5-year PFS (AUC: 0.786 ∼ 0.793). The combined model demonstrated robust performance through Hosmer-Lemeshow test, cross-validation (iteration = 1000), 7:3 validation (chronologically or randomly), and post-hoc subgroup analysis.</div></div><div><h3>Conclusion</h3><div>The advent of vMRE and S-index has streamlined the clinical applications without compromising the value of IVIM technique. Incorporating CPRI and TGT has further enhanced the predictive performance.</div></div><div><h3>Clinical relevance statement</h3><div>Only two b-values are needed to calculate vMRE and S-index, which, along with CPRI and TGT, are pivotal in forecasting long-term survival in patients with NPC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107187"},"PeriodicalIF":4.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143464185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to recent comments on “Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy” 对最近有关 "利用 3D 打印口腔支架为接受放疗的头颈部癌症患者开发和临床实施数字化工作流程 "的评论的答复

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-18 DOI: 10.1016/j.oraloncology.2025.107220

Rance B. Tino , Millicent A. Roach , Gabriela D. Fuentes , Anshuman Agrawal , Mohamed Zaid , Dylan J. Cooper , Nimit Bajaj , Ruitao Lin , Lianchun Xiao , Lauren L. Mayo , Lee R. Wiederhold , Shalin J. Shah , Molly K. Tate , Gregory M. Chronowski , Jay P. Reddy , Megan Mezera , Justin M. Mann , Mark Augspurger , Adegbenga O. Otun , Mark S. Chambers , Eugene J. Koay

引用次数: 0

Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-16 DOI: 10.1016/j.oraloncology.2025.107219

Molly O. Meeker, BS , Akhil Katragadda , Mohammad Bilal Alsavaf , Jack Birkenbeuel , Zachary Wykoff , Songzhu Zhao , Apoorva T. Ramaswamy

Objectives

Dysphagia is a well-known complication of head and neck cancer (HNC) treatment that significantly impacts daily life for survivors. This study aims to characterize esophageal dysmotility identified on high resolution manometry (HRM) in HNC survivors with dysphagia.

Methods

A retrospective chart review of 30 patients who underwent HRM treated for dysphagia between August 1st 2020 to February 2nd, 2023, was conducted. Patients with dysphagia, at least one HRM, and treated in a HNC dysphagia clinic were included. HRM reports were analyzed using Chicago Classification Version 4.0 (CCV4). EGJ outflow obstruction (EGJOO) was validated using endoscopy or radiographic findings. Data was summarized using mean for continuous variables and frequencies for categorical variables.

Results

Of the 30 patients included in our study, 18 (60.0 %) showed evidence of CCV4 dysmotility. The most common subtypes were found to be ineffective motility (n = 6, 33.3 %), followed by EGJOO (n = 5, 27.8 %). Absent contractility and hypercontractile esophagus showed the same frequency (n = 3, 16.7 %), as did achalasia type 1 and type 2 (n = 1, 5.6 %).

Conclusion

Oropharyngeal and pharyngoesophageal dysphagia are well recognized causes of dysphagia, while esophageal dysmotility is an understudied cause of dysphagia in the HNC population. In this study of patients undergoing HRM for workup of their dysphagia after HNC, 60% had evidence of a CCV4 motility disorder, with the most common subtypes being ineffective motility and EGJOO. Therefore, HRM, the gold standard of diagnosis for esophageal dysmotility, should be considered in HNC patients who have symptoms suspicious for dysmotility.

{"title":"Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry","authors":"Molly O. Meeker, BS , Akhil Katragadda , Mohammad Bilal Alsavaf , Jack Birkenbeuel , Zachary Wykoff , Songzhu Zhao , Apoorva T. Ramaswamy","doi":"10.1016/j.oraloncology.2025.107219","DOIUrl":"10.1016/j.oraloncology.2025.107219","url":null,"abstract":"<div><h3>Objectives</h3><div>Dysphagia is a well-known complication of head and neck cancer (HNC) treatment that significantly impacts daily life for survivors. This study aims to characterize esophageal dysmotility identified on high resolution manometry (HRM) in HNC survivors with dysphagia.</div></div><div><h3>Methods</h3><div>A retrospective chart review of 30 patients who underwent HRM treated for dysphagia between August 1st 2020 to February 2nd, 2023, was conducted. Patients with dysphagia, at least one HRM, and treated in a HNC dysphagia clinic were included. HRM reports were analyzed using Chicago Classification Version 4.0 (CCV4). EGJ outflow obstruction (EGJOO) was validated using endoscopy or radiographic findings. Data was summarized using mean for continuous variables and frequencies for categorical variables.</div></div><div><h3>Results</h3><div>Of the 30 patients included in our study, 18 (60.0 %) showed evidence of CCV4 dysmotility. The most common subtypes were found to be ineffective motility (n = 6, 33.3 %), followed by EGJOO (n = 5, 27.8 %). Absent contractility and hypercontractile esophagus showed the same frequency (n = 3, 16.7 %), as did achalasia type 1 and type 2 (n = 1, 5.6 %).</div></div><div><h3>Conclusion</h3><div>Oropharyngeal and pharyngoesophageal dysphagia are well recognized causes of dysphagia, while esophageal dysmotility is an understudied cause of dysphagia in the HNC population. In this study of patients undergoing HRM for workup of their dysphagia after HNC, 60% had evidence of a CCV4 motility disorder, with the most common subtypes being ineffective motility and EGJOO. Therefore, HRM, the gold standard of diagnosis for esophageal dysmotility, should be considered in HNC patients who have symptoms suspicious for dysmotility.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107219"},"PeriodicalIF":4.0,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on sentinel lymph node biopsy in early-stage maxillary cancer

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-15 DOI: 10.1016/j.oraloncology.2025.107221

Xuan Xiao , Mengmeng Lu , Tingjiao Liu , Zhifeng Song

引用次数: 0

Augmented reality in preoperative anterolateral thigh flap perforators positioning: A pilot diagnostic study

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2025-02-14 DOI: 10.1016/j.oraloncology.2025.107189

Bin Wei , Guoxiong Lu , Zhiqiang Bai , David O. Osei-Hwedieh , Yunsheng Chen , Qunxing Li , Zhijun Xie , Peichia Lu , Jiahao Miao , Niu Liu , Jiaying Wu , Hsinyu Lin , Fan Wu , Lizao Zhang , Siqi Ren , Yingying Zhu , Abdo Ahmed Saleh Mohamed , Eduardo Dias-Ribeiro , Xinghui Dong , Kui Jiang , Song Fan

Background

The anterolateral thigh (ALT) flap is the primary choice for healthy and vascularized soft-tissue coverage for appendicular and axial soft tissue reconstruction, especially in the head and neck regions. Nonetheless, there is substantial anatomic variation in ALT perforators that affect flap integrity, survival rates, and donor-site morbidity. Regardless of the ALT flap type, accurate location of perforators can greatly improve surgical success rates and reduce the risk of secondary surgeries. Therefore, we investigated a novel approach for locating perforators.

Method

We utilized augmented reality (AR) technology in combination with a self-designed device, Finder, to locate the perforators of the anterolateral thigh (ALT) flap, and compared its accuracy to that of traditional ultrasound localization.

Result

In this study, 24 patients underwent ALT flap reconstruction, with all flaps surviving except one case of partial necrosis. Comparing the two positioning methods, Ultrasonic color Doppler (UCD) showed a sensitivity of 81.1 % [95 % confidence interval (CI) 64.3 %–91.4 %] and an AUC of 0.70 (95 % CI 0.55–0.86). AR-Finder demonstrated a higher sensitivity of 97.5 % (95 % CI 85.3 %-99.9 %, p = 0.031) and an AUC of 0.90 (95 % CI 0.80–1.01, p = 0.035). The average distance difference from the actual perforator to virtually determined location was 3.54 ± 2.80 mm (95 % CI 2.58–4.50) for AR-Finder and 9.57 ± 5.84 mm (95 % CI 7.75–11.58) for UCD (p < 0.001).

Conclusion

In this pilot study, AR-Finder demonstrated superior accuracy compared to the UCD method for locating perforators in ALT flaps, providing a new and reliable tool for the design and elevation of ALT flaps.

{"title":"Augmented reality in preoperative anterolateral thigh flap perforators positioning: A pilot diagnostic study","authors":"Bin Wei , Guoxiong Lu , Zhiqiang Bai , David O. Osei-Hwedieh , Yunsheng Chen , Qunxing Li , Zhijun Xie , Peichia Lu , Jiahao Miao , Niu Liu , Jiaying Wu , Hsinyu Lin , Fan Wu , Lizao Zhang , Siqi Ren , Yingying Zhu , Abdo Ahmed Saleh Mohamed , Eduardo Dias-Ribeiro , Xinghui Dong , Kui Jiang , Song Fan","doi":"10.1016/j.oraloncology.2025.107189","DOIUrl":"10.1016/j.oraloncology.2025.107189","url":null,"abstract":"<div><h3>Background</h3><div>The anterolateral thigh (ALT) flap is the primary choice for healthy and vascularized soft-tissue coverage for appendicular and axial soft tissue reconstruction, especially in the head and neck regions. Nonetheless, there is substantial anatomic variation in ALT perforators that affect flap integrity, survival rates, and donor-site morbidity. Regardless of the ALT flap type, accurate location of perforators can greatly improve surgical success rates and reduce the risk of secondary surgeries. Therefore, we investigated a novel approach for locating perforators.</div></div><div><h3>Method</h3><div>We utilized augmented reality (AR) technology in combination with a self-designed device, <em>Finder</em>, to locate the perforators of the anterolateral thigh (ALT) flap, and compared its accuracy to that of traditional ultrasound localization.</div></div><div><h3>Result</h3><div>In this study, 24 patients underwent ALT flap reconstruction, with all flaps surviving except one case of partial necrosis. Comparing the two positioning methods, Ultrasonic color Doppler (UCD) showed a sensitivity of 81.1 % [95 % confidence interval (CI) 64.3 %–91.4 %] and an AUC of 0.70 (95 % CI 0.55–0.86). AR-Finder demonstrated a higher sensitivity of 97.5 % (95 % CI 85.3 %-99.9 %, p = 0.031) and an AUC of 0.90 (95 % CI 0.80–1.01, p = 0.035). The average distance difference from the actual perforator to virtually determined location was 3.54 ± 2.80 mm (95 % CI 2.58–4.50) for AR-Finder and 9.57 ± 5.84 mm (95 % CI 7.75–11.58) for UCD (p < 0.001).</div></div><div><h3>Conclusion</h3><div>In this pilot study, AR-Finder demonstrated superior accuracy compared to the UCD method for locating perforators in ALT flaps, providing a new and reliable tool for the design and elevation of ALT flaps.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107189"},"PeriodicalIF":4.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Oral oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀